Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
11:23am, Friday, 05'th May 2023
Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
01:41pm, Thursday, 04'th May 2023
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.
Allogene Therapeutics, Inc. (ALLO) Q1 2023 Earnings Call Transcript
11:49pm, Wednesday, 03'rd May 2023
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer Dr. David Chang - President an
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates
07:02pm, Wednesday, 03'rd May 2023
Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.56 per share a year ago.
Should You Buy Allogene Therapeutics (ALLO) Ahead of Earnings?
12:57pm, Tuesday, 02'nd May 2023
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Wall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 278.19%: Here's is How to Trade
11:25am, Monday, 24'th Apr 2023
The mean of analysts' price targets for Allogene Therapeutics (ALLO) points to a 278.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Allogene Therapeutics (ALLO) Surges 8.4%: Is This an Indication of Further Gains?
03:50am, Monday, 24'th Apr 2023
Allogene Therapeutics (ALLO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Here's Why You Should Add Allogene (ALLO) Stock to Your Portfolio
03:12pm, Wednesday, 19'th Apr 2023
Allogene Therapeutics (ALLO), a top-ranked stock, is currently focused on developing allogenic CAR T therapies for treating cancer.
7 Short-Squeeze Stocks That Could Make You Rich
03:12pm, Thursday, 13'th Apr 2023
While trading with the masses may generally be the wisest approach, contrarian gamblers may accrue dramatic profitability through short-squeeze stocks. To get everyone on the same page, coordinated in
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
08:30am, Thursday, 13'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
7 Short-Squeeze Stocks That Could Explode in April
02:07pm, Thursday, 30'th Mar 2023
While an extremely risky proposition, short-squeeze stocks – as meme traders demonstrated – can occasionally yield radical profitability. However, you don't want to just pick any beaten-down secur
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
12:56pm, Thursday, 30'th Mar 2023
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
After Plunging -23.01% in 4 Weeks, Here's Why the Trend Might Reverse for Allogene Therapeutics (ALLO)
11:17am, Monday, 06'th Mar 2023
Allogene Therapeutics (ALLO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
08:30am, Thursday, 02'nd Mar 2023
SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloC
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
11:18am, Wednesday, 01'st Mar 2023
Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.
